⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

November 17, 2021Clinical Cancer ResearchOpen Access

Tepotinib Efficacy and Safety in Patients with MET Exon 14 Skipping NSCLC: Outcomes in Patient Subgroups from the VISION Study with Relevance for Clinical Practice

View Full Paper

Ask AI

Bookmark

Share

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

A 2021 study studied this question.

synapsesocial.com/papers/6aabc9f84f75eede048354c2 https://doi.org/10.1158/1078-0432.ccr-21-2733

View Full Paper

Ask AI

Bookmark

Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Budget impact of capmatinib for adults with metastatic non-small cell lung cancer harboring a <i>MET</i> exon 14 skipping mutation in the United States2021 · 12 citations
2Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer2020 · 1,038 citations
3First-in-Man Phase I Trial of the Selective MET Inhibitor Tepotinib in Patients with Advanced Solid Tumors2019 · 92 citations
4<i>MET</i> Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent <i>MET</i> Genomic Amplification and c-Met Overexpression2016 · 703 citations
5Tepotinib in Non–Small-Cell Lung Cancer with <i>MET</i> Exon 14 Skipping Mutations2020 · 892 citations